Kao Corporation 4452
Kao is a sleeping FMCG giant whose under-ambition, inefficiency, and lack of focus have destroyed EVA; adding five independent directors with FMCG operating experience can unlock peer-level returns.
Thesis
Kao Corporation owns a coveted portfolio of FMCG brands — Bioré, Curél, Kanebo, Molton Brown, John Frieda, Oribe — in categories where L'Oréal, Beiersdorf, and Unilever are compounding profitably, yet Kao trails every global peer on ROIC, operating margin, and R&D productivity. Oasis argues three fundamental flaws explain the gap: under-ambition (an 11% K27 ROIC target below every peer, 10.5% marketing spend vs peers' mid-teens), inefficiency (consumer-products operating margin collapsing from ~13% in 2020 into low-single-digits in 2023, EVA swinging to -JPY 43.8bn by Q4 2023, research-capital returns falling from 15.5 to 9.2), and lack of focus (management admits too many businesses and ~20% unproductive SKUs while President Hasebe pushes 'Another Kao' into enzyme batteries and medical). To fix this, Oasis proposes five independent director candidates with hands-on FMCG operating experience and twelve pointed questions the external directors must answer.
SCQA
Kao owns a world-class stable of FMCG and cosmetics brands (Bioré, Curél, Kanebo, Molton Brown, John Frieda, Oribe) competing in categories where L'Oréal, Beiersdorf, and Unilever are delivering profitable global growth.
Three self-inflicted flaws — under-ambition (11% ROIC target vs peers' 15-25%), inefficiency (consumer operating margin collapsing, EVA swinging to -JPY 43.8bn, R&D returns falling to 9.2), and lack of focus (too many SKUs, enzyme-battery and medical distractions) — cap value creation.
Kao's external directors should accept Oasis' five independent FMCG-operator nominees, lift financial targets, redirect marketing spend abroad, prune 20% of unproductive SKUs, and abandon 'Another Kao' diversification detours.
Growing consumer products just in line with global peers would add roughly JPY 30bn of revenue and nearly JPY 7bn of EBITDA by 2027 on Curél alone, with further upside if margins rerate toward P&G/Colgate levels.
The three reasons
- 1
Kao trails every global FMCG peer on ROIC, and its own K27 target (11%) cements the gap
- 2
Consumer-products operating margin has collapsed from ~13% in 2020 to low-single-digits in 2023, with EVA turning sharply negative
- 3
Management admits 'too many businesses' and 20% unproductive SKUs while chasing enzyme batteries and medical — classic lack of focus
Primary demands
- Consider Oasis' slate of five independent director candidates (FMCG supply chain, consumer goods FP&A, beauty CMO, digital transformation, FMCG turnaround)
- Raise K27 ROIC target above the 11% floor that trails every global FMCG peer
- Increase marketing and advertising spend from ~10.5% of revenue to levels closer to L'Oréal/Unilever/P&G
- Rationalize the brand portfolio and cut ~20% of unproductive SKUs acknowledged by management
- Exit or deprioritize 'Another Kao' diversification bets (enzyme batteries, medical) that lack strategic fit
- Answer the 12 specific governance questions posed to outside directors
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- L'Oréal (FMCG peer benchmark on ROIC and operating margin)
- Beiersdorf (derma-cosmetics scaling precedent for Curél)
- Galderma (derma-cosmetics scaling precedent for Curél)
- Unilever, P&G, Colgate-Palmolive, Kimberly-Clark (peer-group ROIC and margin benchmarks)
Notable slides (6)
Notes
Presentation delivered directly to Kao's outside directors rather than a public campaign launch — part of Oasis' ongoing 'A Better Kao' campaign. Cover dated December 5, 2024. Several slides are cross-referenced with 'As featured in A Better Kao' badges, confirming this is a follow-up document. Deck is structured entirely as governance questions posed to external directors, with director-candidate profiles in the opening section. No explicit stake disclosure and no target price — the 'reward' is framed qualitatively and via Curél/overseas revenue sensitivities. Author is the firm; no individual signatory on cover. Founder Seth Fischer is publicly associated with the campaign but not named on this deck.